ライフサイエンスコーパス: be developed

1 Our approach could also be developed into a rehabilitative/assistive tool that can re

2 the liver could increase their antifibrotic activities and be developed for treatment of patients with liver fibrosis.

3 affects the brain and behavior, (2) whether medications can be developed to treat cannabis use disorder, and (3) whether

4 biosensor with highly biocompatibility and nontoxicity, can be developed for detection of other DNA biomarkers.

5 The technique can be developed further for producing catalyst-free agents via S

6 and examples are given of the types of biosensors that can be developed.

7 ta suggest that 12,13-diHOME, or a functional analog, could be developed as a treatment for metabolic disorders.

8 at the combination of shRNAs against HBV and TGF-beta could be developed into a viable treatment for human HBV infection.

9 population for ZIKV treatment, therapeutic candidates could be developed through a 2-stage path.

10 d suggest that a time-dependent series of extractions could be developed as a functional assay to determine the dissoluti

11 novative therapies based on n-3 DPA-derived mediators could be developed to enable antiinflammatory and tissue protective

12 inery exists in ALB and a potential RNAi-based method could be developed for controlling this insect.

13 The identified microRNAs could be developed as biomarkers of kidney diseases and might be in

14 Organoids could be developed over extended periods (more than 9 months), allo

15 Fluorine-labeled analogs, that could be developed as PET-based imaging tracers, were evaluated in

16 rom reinfection, suggesting that an effective vaccine could be developed.

17 data after outpatient mental health specialty visits could be developed to predict suicides among outpatients.

18 ive tool for investigating brain glycosylation, which could be developed in to brain mapping applications, but also serve

19 icacy when tested in a novel murine challenge model and may be developed into future therapeutics.

20 ry requires a combination of both device and drug, each may be developed in conjunction, or separately, which are importa

21 e perspective that a generalizable model of RNA folding may be developed from understanding of the folding properties of

22 These results suggest that NA treatment may be developed into a potential therapy for malignant glioma.

23 summary, our results suggest that compound 1 and DBL might be developed as naturally-based biocontrol agents.

24 Strategies to block PD-L1, TIM3, and LAG3 might be developed for treatment of primary liver cancer.

25 to reduce triglyceride levels, by increasing MIR122, might be developed for treatment of metabolic syndrome.

26 Agents designed to activate SIRT1 might be developed as treatments for IBDs.

27 AEG-1 inhibitory strategies might be developed as a potential therapeutic intervention in NASH

28 provides guidelines for how an improved DoC taxonomy might be developed.

29 rly treatment; therefore, a simple and accurate device must be developed for this purpose.

30 This approach can potentially be developed into a single-molecule toolbox to investigate th

31 Instead, chemical formulations could potentially be developed to achieve novel pharmacokinetics, without consi

32 at a combination of anti-CD40/CpG and IC/anti-CTLA-4 should be developed for clinical testing as a potentially effective

33 trategies for biomolecular recognition and detection should be developed into reliable and inexpensive platforms.

34 In the present study a simple colorimetric sensor should be developed and tested for the real-time detection of Cyt c

35 correct vitamin D deficiency in patients with sepsis should be developed.

36 Services should be developed to better diagnose and manage these patients.

37 Targeting NLRP3 inflammasome pathway mediators could thus be developed as therapeutic interventions to alleviate or pre

38 tions, often hinders the ability of a candidate antibody to be developed and manufactured.

39 ample polyethylene glycol) and methods for consolidation to be developed.

40 As new strategies continue to be developed, it is equally important to continue to refine o

41 nvasive methods of MSCs delivery to the brain still have to be developed.

42 Modulators of Siglec function are likely to be developed and investigated clinically in a cancer context

43 lack such level of control, alternative strategies need to be developed and adjusted to the specifics of the field.

44 nt of new information, new rules for crystal growth need to be developed and tested.

45 impler and more cost-effective purification methods need to be developed compared to chromatography to enhance its commer

46 also guide which technologies should be applied, or need to be developed, to produce foods that support efficient microbi

47 chemical parameters and more specialized procedures need to be developed.

48 methods which can handle large-scale problems still need to be developed.

49 efine dose and pharmacokinetics of T cell therapies need to be developed.

50 ore dependable and responsive diagnostic testing has yet to be developed.